spacer
home > ebr > summer 2018 > alternative approaches
PUBLICATIONS
European Biopharmaceutical Review

Alternative Approaches

Novel cancer therapies extend far beyond traditional chemo- and radiotherapy approaches. Specific small-molecule inhibitors or antibodies targeting epitopes at the surface of cancer cells are employed to fight cancer cells. Antibody-drug conjugates deliver toxic or radioactive compounds directly to the tumour cell, and bispecific antibodies present tumour cells to the immune system. Even more advanced immune therapies such as CAR-T techniques boost the immune system by modifying T-cells. Stem cell and gene editing-based therapies are getting off the starting blocks, raising hopes towards more effective and safer cancer therapies.

Despite their structural and molecular diversity, these novel therapies have one thing in common: unlike conventional therapies, which attack every fast-dividing cell, they aim to specifically target features unique to tumour cells, allowing the use of highly potent therapies while minimising side effects on healthy tissue. Therefore, identification and characterisation of target structures is a prerequisite to the success of novel cancer therapies.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Ute Boronowsky is a freelance science and marketing writer, translator, and journalist, covering topics relevant to the biotech and pharma industry. She received a PhD in biochemistry from the University of Bochum, Germany, did post-doctoral research in biochemistry at UCLA, US, and holds a degree in science journalism from the mibeg Institute for Media in Cologne, Germany. Ute has more than 15 years working experience from sales and marketing positions in the biotech industry and is co-founder of the start-up company Cube Biotech. She is member of the Chartered Institute of Linguists, UK, and of the Science Inbound writer’s network.
spacer
Dr Ute Boronowsky
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Standardized Syringe Testing with Zwick

In today's world, the medical industry is continually faced with the challenge of providing patients with better care. Glass syringes that deliver drugs to patients are an essential part of this care. These glass syringes are typically used in connection with injection needles, needless Luer locks, adapters, and transfer devices.
More info >>

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

 
Industry Events

PDA Universe of Pre-Filled Syringes and Injection Devices

8 October - 9 November 2018, Loews Royal Pacific, Orlando, FL

At the 2018 PDA Universe of Pre-filled Syringes and Injection Devices,industry and regulatory experts will share experiences, new developments, regulatory considerations, challenges, and industry trends and best practices. This is a must-attend event for all industry professionals involved in the development, manufacturing, testing, or marketing of pre-filled syringes and injection devices.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement